ADAM22, Expressed in Normal Brain but not in High-Grade Gliomas, Inhibits Cellular Proliferation via the Disintegrin Domain
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To study the expression and function of the brain-specific proteinase deficient disintegrins, ADAM11 and ADAM22 (a disintegrin and metalloproteinase). METHODS: Specimens of low- and high-grade gliomas and normal brain were analyzed for ADAM11 and ADAM22 expression using Western blotting. The effects of overexpression of ADAM11 and ADAM22 in glioma cells on growth were analyzed using bromodeoxyuridine incorporation linked to immunocytochemistry. Similarly analyzed were the effects on cell proliferation of bacterially expressed glutathione S-transferase fusion proteins with the disintegrin domain of ADAM11 and ADAM22. RESULTS: ADAM22 is expressed in normal brain and some low-grade gliomas, but not in high-grade gliomas, whereas ADAM11 is expressed in all low- and high-grade gliomas. In vitro, ADAM22 inhibits cellular proliferation of glioma derived astrocytes. The growth inhibition appears to be mediated by interactions between the disintegrin domain of ADAM22 and specific integrins expressed on the cell surface. This growth inhibition can be avoided by over-expression of integrin linked kinase. CONCLUSION: ADAM22, a brain-specific cell surface protein, mediates growth inhibition using an integrin dependent pathway. It is expressed in normal brain but not in high-grade gliomas. A related protein, ADAM11, has only a minor effect on cell growth, and its expression is unchanged in low- and high-grade gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional analysis of secreted and transmembrane proteins critical to mouse development.
Mitchell, K. J., Pinson, K. I., Kelly, O. G., Brennan, J., Zupicich, J., Scherz, P., Leighton, P. A., Goodrich, L. V., Lu, X., Avery, B. J., et al. (2001) · Nature Genetics · doi:10.1038/90074 · Cited by 400
Cited by
EDWARDS, D., HANDSLEY, M., & PENNINGTON, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,161
The ADAMs: signalling scissors in the tumour microenvironment
Murphy, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2459 · Cited by 451
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., & Cataldo, D. (2008) · Biochimie · doi:10.1016/j.biochi.2007.08.008 · Cited by 266
Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?
Rivera, S., Khrestchatisky, M., Kaczmarek, L., Rosenberg, G. A., & Jaworski, D. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3467-10.2010 · Cited by 223
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Metadata
- Authors
- D'Abaco, G. M., Ng, K., Paradiso, L., Godde, N. J., Kaye, A., & Novak, U.
- Venue
- Neurosurgery
- Published
- 2006-01-01
- Volume
- 58
- Issue
- 1
- Pages
- 179-186
- ISSN
- 0148-396X (ISSN-L)
- 1524-4040
- OpenAlex
- W1992398154
- Cited by
- 51
- References
- 1
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ADAM22, Expressed in Normal Brain but not in High-Grade Gliomas, Inhibits Cellular Proliferation via the Disintegrin Domain. https://app.cochat.ai/papers/10.1227/01.neu.0000192363.84287.8b
- The paper
- D'Abaco, G. M., Ng, K., Paradiso, L., Godde, N. J., Kaye, A., & Novak, U. (2006). ADAM22, Expressed in Normal Brain but not in High-Grade Gliomas, Inhibits Cellular Proliferation via the Disintegrin Domain. Neurosurgery. https://doi.org/10.1227/01.neu.0000192363.84287.8b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.